What is Applied Stemcell?
Applied Stemcell operates as a specialized Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) focused on the intersection of gene editing and stem cell therapy. The company provides critical infrastructure for the advancement of genetic medicine through its two primary technological pillars: the CRISPR/TARGATT genome editing platform and its GMP-grade induced pluripotent stem cell (iPSC) services. By bridging the gap between early-stage research and clinical-grade manufacturing, Applied Stemcell serves as a vital partner for pharmaceutical and biotech entities aiming to navigate the complexities of therapeutic development. Its market position is defined by a commitment to high-precision, scalable solutions that address the technical bottlenecks inherent in modern gene therapy workflows.
How much funding has Applied Stemcell raised?
Applied Stemcell has raised a total of $25M across 5 funding rounds:
Series B
$1.9M
Series C
$2.6M
Series D
$19M
Debt
$1M
Debt
$500K
Series B (2010): $1.9M, investors not publicly disclosed
Series C (2013): $2.6M, investors not publicly disclosed
Series D (2016): $19M supported by BioSciKin, Vi-Ventures, Hermed Capital, and Ping An Ventures
Debt (2020): $1M featuring PPP
Debt (2021): $500K backed by PPP
Key Investors in Applied Stemcell
BioSciKin
BioSciKin is an open platform for life science entrepreneurs in China, focusing on novel therapeutics, medical devices, and mobile healthcare services through R&D-oriented incubation parks.
Vi-Ventures
A boutique investment firm specializing in TMT and healthcare technology, facilitating cross-border growth between China, the United States, and Israel.
Hermed Capital
A private investment firm providing flexible working capital solutions and financial support to businesses, driven by a focus on long-term prosperity and strategic partnership.
What's next for Applied Stemcell?
With the recent capital injection, Applied Stemcell is expected to prioritize the expansion of its GMP-grade manufacturing capacity to meet the rising demand for iPSC-based therapies. The company's strategic roadmap likely includes deepening its footprint in the global life sciences market, potentially through enhanced R&D collaborations and the optimization of its CRISPR/TARGATT platform for broader therapeutic applications. As the firm transitions into its next phase of maturity, the focus will remain on maintaining regulatory excellence and operational agility, ensuring that its technological assets remain at the forefront of the rapidly evolving cell and gene therapy ecosystem. Investors will be monitoring the company's ability to translate this financial support into accelerated clinical milestones and expanded market share.
See full Applied Stemcell company page
